We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VYLOY (Astellas Pharma Australia Pty Ltd)
Product name
VYLOY
Date registered
Evaluation commenced
Decision date
Approval time
230 (255 working days)
Active ingredients
zolbetuximab
Registration type
NCE/ NBE
Indication
VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GOJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive (see section 4.2 Dose and method of administration).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.